Key Points
The 2,100 shares were acquired for ~$100,000 on August 5, 2026.
This transaction represents a 14% increase in total direct equity holdings.
The acquisition was conducted as a direct purchase, expanding the insider's total direct position to 17,160 shares.
The purchase was executed following a one-year total return of -54% as of the August 5, 2026 transaction date.
David C. Habiger, a Director at Boston Scientific Corporation(NYSE:BSX), purchased 2,100 shares of Common Stock on August 5, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares purchased | 2,100 |
| Transaction value | $99,939 |
| Post-transaction shares (directly held) | 17,160 |
| Post-transaction value | $819,218.40 |
Transaction value based on SEC Form 4 weighted average purchase price ($47.59); post-transaction value based on August 5, 2026 market close ($47.74).
Key questions
- How does this purchase align with current valuation and historical performance?
Habiger acquired the equity at a fraction of a penny less than $47.59 per share, a period during which the stock had declined 54% over the 12 months ending on the Aug. 5, 2026 transaction date. - What is the scale of the insider's total ownership interest?
Following this transaction, Habiger maintains a direct ownership interest of 17,160 shares, representing about one one-thousandth of 1% of the $73.3 billion medical device company. - What were the specific execution mechanics of this trade?
The director utilized a weighted average pricing structure for the transaction, with individual purchase prices ranging from $47.21 to $47.98 per share. - How has the stock performed relative to this transaction price recently?
The stock was priced at $49.30 as of the Aug. 6, 2026 market close, which is approximately 3.59% above the weighted average price paid by the insider.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-06) | $49.30 |
| Market Capitalization | $73.3 billion |
| Revenue (TTM) | $21.0 billion |
| Net Income (TTM) | $3.7 billion |
Company Snapshot
- Boston Scientific Corporation designs, manufactures, and commercializes a comprehensive portfolio of innovative medical devices across three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular, addressing diverse interventional medical specialties globally.
- The company generates revenue by developing and distributing specialized medical technology solutions that enable healthcare providers to deliver advanced therapeutic and diagnostic interventions across multiple clinical disciplines.
- Boston Scientific serves hospitals, healthcare systems, and interventional specialists worldwide, targeting patients requiring advanced medical device solutions across cardiology, gastroenterology, neurology, and surgical specialties.
Boston Scientific Corporation is a global leader in medical technology with approximately 59,000 employees and a market capitalization of $73 billion. The company maintains a diversified product portfolio across three strategic business segments, positioning itself as a comprehensive provider of innovative medical devices for interventional procedures. With trailing twelve month (TTM) revenues of $21 billion and net income of $3.7 billion, Boston Scientific demonstrates significant scale and profitability within the medical device sector, supported by its commitment to advancing therapeutic solutions across multiple clinical specialties.
What this transaction means for investors
There are multiple reasons a company insider may sell shares in the business. One reason could be the need to raise cash to meet a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company’s future.
However, there is only one reason an insider buys stock: they believe the share price is going up.
By that investor’s rule of thumb, Habiger’s purchase of $100,000 worth of Boston Scientific shares is bullish. Adding to the bullishness is the fact that studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.
At first glance, an investor may question why an insider like Habiger, best known as the vice chair of J.D. Power, would be bullish on Boston Scientific. The company has been having a tough 2026, with management cutting revenue guidance twice due to a competitive marketplace. But the company’s future looks brighter thanks to acquisitions that have created a robust pipeline of new products set to hit the market in 2027 through 2029. Management is also pushing a restructuring that promises to cut $500 million of fat from operations going into 2027.
Even a relatively small-scale purchase like Habiger is positive — no one likes to lose money. And since he has been a director since 2024, he surely knows enough about the business to feel good about its future.
An insider purchase of stock is no guarantee shares will go higher, but a buying statement by a director like Habiger is a signal that investors should take a close look at Boston Scientific shares.
Should you buy stock in Boston Scientific right now?
Before you buy stock in Boston Scientific, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Boston Scientific wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of August 10, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
